scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1003586492 |
P356 | DOI | 10.1186/1750-1326-8-42 |
P932 | PMC publication ID | 3816305 |
P698 | PubMed publication ID | 24160175 |
P5875 | ResearchGate publication ID | 258101023 |
P50 | author | Lisa M Ellerby | Q91624962 |
P2093 | author name string | Cathy Vitelli | |
Theodora Papanikolaou | |||
Mahru C An | |||
Carlotta E Duncan | |||
Caitlin Rugani | |||
P2860 | cites work | Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion | Q24310393 |
Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors | Q24316293 | ||
Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes | Q24338317 | ||
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 | Q24599788 | ||
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice | Q24656405 | ||
Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7 | Q28189688 | ||
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein | Q28216526 | ||
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo | Q28483335 | ||
Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease | Q28486205 | ||
Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta | Q28565080 | ||
Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation | Q28566835 | ||
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3 | Q28609763 | ||
Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease | Q28732195 | ||
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model | Q28743986 | ||
Histone acetylation, acetyltransferases, and ataxia--alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders | Q30433574 | ||
Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration | Q33854083 | ||
Histone deacetylase inhibitors reduce polyglutamine toxicity | Q33953013 | ||
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing | Q34019122 | ||
HDAC3 is a critical negative regulator of long-term memory formation | Q34158695 | ||
Histone deacetylase complexes promote trinucleotide repeat expansions | Q34169694 | ||
Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease | Q34358457 | ||
Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. | Q34545446 | ||
Regulation of histone deacetylase activities | Q34550653 | ||
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
The histone deacetylase-3 complex contains nuclear receptor corepressors | Q35155073 | ||
Spinocerebellar ataxia type 7 associated with pigmentary retinal dystrophy | Q35565116 | ||
Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death | Q36318929 | ||
Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain | Q36321289 | ||
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders | Q36599926 | ||
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control | Q36639688 | ||
Histone deacetylases: focus on the nervous system | Q36832256 | ||
Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity | Q37020186 | ||
HDAC inhibitors and neurodegeneration: at the edge between protection and damage | Q37685428 | ||
Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). | Q38963048 | ||
Distribution of histone deacetylases 1-11 in the rat brain | Q40225359 | ||
Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. | Q40329109 | ||
A role for both wild-type and expanded ataxin-7 in transcriptional regulation | Q42479386 | ||
Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment | Q42719817 | ||
SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. | Q43258139 | ||
Ataxin-7 expression analysis in controls and spinocerebellar ataxia type 7 patients | Q43609121 | ||
Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. | Q45300254 | ||
Molecular genetic analysis of autosomal dominant cerebellar ataxia with retinal degeneration (ADCA type II) caused by CAG triplet repeat expansion | Q48039672 | ||
Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport | Q48435478 | ||
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions | Q48464946 | ||
A conditional pan-neuronal Drosophila model of spinocerebellar ataxia 7 with a reversible adult phenotype suitable for identifying modifier genes. | Q52677435 | ||
SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types | Q57387383 | ||
Distribution of ataxin-7 in normal human brain and retina | Q57969436 | ||
An expanded CAG repeat sequence in spinocerebellar ataxia type 7 | Q57970953 | ||
Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation | Q60623894 | ||
P4510 | describes a project that uses | ImageQuant | Q112270642 |
P921 | main subject | spinocerebellar ataxia type 7 | Q22443706 |
P304 | page(s) | 42 | |
P577 | publication date | 2013-10-27 | |
P1433 | published in | Molecular Neurodegeneration | Q15817329 |
P1476 | title | Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model | |
P478 | volume | 8 |
Q49884282 | Complex neuroprotective and neurotoxic effects of histone deacetylases. |
Q35403365 | Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates. |
Q34309571 | Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury |
Q38215303 | Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors |
Q26764958 | Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease |
Q33879684 | Pulling complexes out of complex diseases: Spinocerebellar Ataxia 7. |
Q37445508 | Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells |
Q57072576 | Roles of Post-translational Modifications in Spinocerebellar Ataxias |
Q50050224 | Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury |
Q33784471 | The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1 |
Q99587952 | Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation |
Search more.